Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs

A prospective study of 120 patients with cancer was carried out to evaluate effects of potentially cardiotoxic anticancer drugs using radionuclide cardiovascular studies. Five groups were studied: 7 patients received 4'-demethoxydaunorubicin, 23,4'-deoxydoxorubicin, 34,4'-epidoxorubicin, 49 mitoxantrone and 7 4'(9-acridinylamino)-methan-sulphon-m-anisidide (amsa). Two patients receiving 4'-demethoxydaunorubicin, 7 on 4'-deoxydoxorubicin, 11 on 4'-epidoxorubicin, 21 on mitoxantrone and 3 on amsa had falls of ≥ 10% in their left ventricular ejection fraction. Using data from this study, the recommended guidelines are set out. 33 refs., 2 tabs